References
- Abe H, Mori T, Kawai Y, et al (2013). Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2- positive breast cancer patients. Asian Pac J Cancer Prev, 14, 4843-6. https://doi.org/10.7314/APJCP.2013.14.8.4843
- Baselga J, Perez EA, Pienkowski T, Bell R (2006). Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11, 4-12 https://doi.org/10.1634/theoncologist.11-90001-4
- Bria E, Cuppone F, Fornier M, et al (2008). Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A metaanalysis of the randomized trials. Breast Cancer Res Treat, 109, 231-9. https://doi.org/10.1007/s10549-007-9663-z
- Bowles EJ, Wellman R, Feigelson HS et al (2012). Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst, 104, 1293-1305. https://doi.org/10.1093/jnci/djs317
- Campiglio M, Bufalino R, Sasso M, et al (2013). Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat, 141, 101-10. https://doi.org/10.1007/s10549-013-2658-z
- Carter CL, Allen C, Henson DE (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181. https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
- Dahabreh IJ, Linardou H, Siannis F, et al (2008). Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist, 13, 620-630. https://doi.org/10.1634/theoncologist.2008-0001
- Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045
- Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 19, 403. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
- Gabos Z, Thoms J, Ghosh S, et al (2010). The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat, 124, 187-94. https://doi.org/10.1007/s10549-010-1135-1
- Gianni L, Dafni U, Gelber RD et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-244. https://doi.org/10.1016/S1470-2045(11)70033-X
- Goldhirsch A, Piccart-Gebhart MJ, Procter et al (2013). HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res, 72, 103
- Koscielny S, Tubiana M, Le MG, et al (1984). Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer, 49, 709. https://doi.org/10.1038/bjc.1984.112
- Krell J, James CR, Shah D, et al (2011). Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. Clin Breast Cancer, 11, 153-60. https://doi.org/10.1016/j.clbc.2011.03.012
- Mansell J, Monypenny IJ, Skene AI, et al (2009). Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat, 117, 91-8 https://doi.org/10.1007/s10549-008-0291-z
- Mariani G, Fasolo A, De Benedictis E, et al (2009). Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol, 6, 93-104. https://doi.org/10.1038/ncponc1298
- Metzger-filho O, Procter M, De Azambuja AE et al (2013). Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol, 31, 1954-60. https://doi.org/10.1200/JCO.2012.46.2440
- Mittendorf EA, Wu Y, Scaltriti M, et al (2009). Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res, 15, 7381-8. https://doi.org/10.1158/1078-0432.CCR-09-1735
- Palmieri C, Shah D, Krell J et al (2011). Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer, 11, 93-102. https://doi.org/10.1016/j.clbc.2011.03.001
- Perez EA, Romond EH, Suman VJ, et al (2011). Four year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 29, 3366-73. https://doi.org/10.1200/JCO.2011.35.0868
- Perez EA, Romond EH, Suman VJ, et al (2014). Trastuzumab Plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 32, 3744-52. https://doi.org/10.1200/JCO.2014.55.5730
- Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. https://doi.org/10.1038/35021093
- Piccart-Gebhart M, Procter M, Leyland-Jones B, et al (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72. https://doi.org/10.1056/NEJMoa052306
- Pohlmann PR, Mayer IA, Mernaugh R (2009). Resistance to trastuzumab in breast cancer. Clin Cancer Res, 15, 7479-91 https://doi.org/10.1158/1078-0432.CCR-09-0636
- Prat A, Perou CM (2010). Deconstructing the molecular portraits of breast cancer. Mol Oncol, 5, 5-23.
- Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
- Shaffer R, Tyldesley S, Rolles M, et al (2009). Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol, 90, 122-6. https://doi.org/10.1016/j.radonc.2008.09.003
- Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against her 2 for metastatic breast cancer that overexpresses her 2. N Engl J Med, 344, 783-892. https://doi.org/10.1056/NEJM200103153441101
- Smith I, Procter M, Gelber RD et al (2007). 2-Year follow up of trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36 https://doi.org/10.1016/S0140-6736(07)60028-2
- Spielmann M, Roche H, Delozier T, et al (2009). Trastuzumab for patients with axillary node- positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol, 27, 6129-34. https://doi.org/10.1200/JCO.2009.23.0946
- Suter TM, Procter M, van Veldhuisen DJ, et al (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol, 25, 3859-65. https://doi.org/10.1200/JCO.2006.09.1611
- Tai CJ, Pan CK, Chen CS et al (2013). Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer. Asian Pac J Cancer Prev, 14, 1981-4. https://doi.org/10.7314/APJCP.2013.14.3.1981
- Vaz-Luis I, Winer EP, Lin NU et al (2013). Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol, 24, 283-91 https://doi.org/10.1093/annonc/mds286
- Vaz-Luis I, Ottesen RA, Hughes ME, et al (2012). Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res, 1, 129.
- Vaz-Luis I, Seah D, Olson EM, et al (2013). Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer, 13, 254-63. https://doi.org/10.1016/j.clbc.2013.02.010
- Zhu ZL, Zhang J, Chen ML, Li K (2013). Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Asian Pac J Cancer Prev, 14, 7111-6. https://doi.org/10.7314/APJCP.2013.14.12.7111